18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnosis and Post-Therapeutic Treatment in a Patient with an Early Stage of Retroperitoneal Fibrosis

Purpose. The purpose of the article is to evaluate the diagnostic significance of positron emission tomography / computed tomography with 18F -fluorodeoxyglucose (18F -FDG PET/CT) for the diagnosis of prosthetic endocarditis. Methods of research. The study included 82 patients with suspected prosthetic endocarditis in accordance with the criteria proposed by Duke University [1-5]. The patients received hospital treatment at the State Institution RSPC "Cardiology" from January 2016 to March 2021. The study was of a prospective, non-randomized, single-center cohort design. The duration of the monitor period was 12 months from the moment of patients’ inclusion in the study. Whole-body positron emission tomography / computed tomography (PET/CT) examinations were performed in 82 patients. 27 patients were selected for surgical treatment. Conservative treatment group included 16 patients. 27 patients were selected into the observation group, they were suspected to have prosthetic heart valve infection in the primary referral and underwent PET/CT scanning, according to which the diagnosis of prosthetic endocarditis was excluded. The event under the study did not develop in this group during the year of observation. Results and conclusion. The history of infective endocarditis was not statistically significant and did not increase the risk of developing prosthetic endocarditis in the sample presented. The Duke criteria are less reliable in establishing the diagnosis of prosthetic endocarditis. The median number of days from the date of the first prosthesis implantation to the onset of prosthetic endocarditis was about 4 years. This study revealed that the development of the infectious process in the area of the prosthesis was noted in a more distant postoperative period compared to literature data. Histological confirmation of infection was noted in 100% (27 patients) of cases in reoperated patients. The presence of a more formidable complication such as valve ring abscess located mainly in the projection of the aortic valve ring was quite common in both groups. Presepsin and Interleukin-6 have a statistically significant (U = 394,50 p = 0,01 and U = 94,50 p = 0.004) value in the prognosis of prosthetic endocarditis. Considering the data obtained from ROC analysis, it can be said that the cut-off point at which it is possible to diagnose prosthetic endocarditis based on PETCT is 2.85. The presented methods for the interpretation of whole-body FDG-PET/CT images of patients with suspected infectious complications after cardiac surgery, as well as with the presence of prosthetic endocarditis, show high sensitivity and specificity.

Download Full-text

Adenoid cystic carcinoma of trachea: Findings on 18F FDG positron emission tomography-computed tomography

Indian Journal of Nuclear Medicine ◽

10.4103/ijnm.ijnm_172_18 ◽

2019 ◽

Vol 34 (3) ◽

pp. 249

Author(s):

Rakesh Kumar ◽

Sarthak Tripathy ◽

ShamimAhmed Shamim ◽

Abhishek Behera ◽

Chandrasekhar Bal

Keyword(s):

Computed Tomography ◽

Positron Emission Tomography ◽

Adenoid Cystic Carcinoma ◽

Emission Tomography ◽

Adenoid Cystic ◽

Positron Emission ◽

18F Fdg

Download Full-text

Clinical Impact of 18F-FDG PET/CT in the Diagnostic Workup of Pancreatic Ductal Adenocarcinoma: A Systematic Review

Diagnostics ◽

10.3390/diagnostics10121042 ◽

2020 ◽

Vol 10 (12) ◽

pp. 1042

Author(s):

Annachiara Arnone ◽

Riccardo Laudicella ◽

Federico Caobelli ◽

Priscilla Guglielmo ◽

Marianna Spallino ◽

...

Keyword(s):

Computed Tomography ◽

Positron Emission Tomography ◽

Pancreatic Ductal Adenocarcinoma ◽

Fdg Pet ◽

Emission Tomography ◽

Ductal Adenocarcinoma ◽

Positron Emission ◽

Pet Ct ◽

18F Fdg ◽

Fdg Pet Ct

In this review, the performance of fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) in the diagnostic workup of pancreatic ductal adenocarcinoma (PDAC) is evaluated. A comprehensive literature search up to September 2020 was performed, selecting studies with the presence of: sample size ≥10 patients and index test (i.e., “FDG” or “18F-FDG” AND “pancreatic adenocarcinoma” or “pancreas cancer” AND “PET” or “positron emission tomography”). The methodological quality was evaluated using the revised quality assessment of diagnostic accuracy studies (QUADAS-2) tool and presented according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. Basic data (authors, year of publication, country and study design), patients’ characteristics (number of enrolled subjects and age), disease phase, type of treatment and grading were retrieved. Forty-six articles met the adopted research criteria. The articles were divided according to the considered clinical context. Namely, besides conventional anatomical imaging, such as computed tomography (CT) and magnetic resonance imaging (MRI), molecular imaging with FDG PET/CT is an important tool in PDAC, for all disease stages. Further prospective studies will be necessary to confirm the cost-effectiveness of such imaging techniques by testing its real potential improvement in the clinical management of PDAC.

Download Full-text

P025 (0033) METABOLIC TUMOR VOLUME BY POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY FOR DECIDING THE THERAPEUTIC MODALITY IN PATIENTS WITH EARLY STAGE HODGKIN'S LYMPHOMA

HemaSphere ◽

10.1097/01.hs9.0000547875.10470.15 ◽

2018 ◽

Vol 2 (S3) ◽

pp. 12 ◽

Cited By ~ 1

Keyword(s):

Computed Tomography ◽

Positron Emission Tomography ◽

Hodgkin’S Lymphoma ◽

Tumor Volume ◽

Early Stage ◽

Metabolic Tumor Volume ◽

Hodgkin's Lymphoma ◽

Emission Tomography ◽

Therapeutic Modality ◽

Positron Emission

Download Full-text

Abstract P5-01-08: Preoperative Positron Emission Tomography/Computed Tomography (PET/CT) and18F-Fluorodeoxyglucose (18F-FDG) Compared with Conventional Assessment in Patients with Early Primary Breast Cancer: Preliminary Results of a Prospective Study

10.1158/0008-5472.sabcs10-p5-01-08 ◽

2010 ◽

Author(s):

MB Petersen ◽

AK Berthelsen ◽

V Timmermans-Wielenga ◽

N Kroman ◽

T Binderup ◽

...

Keyword(s):

Breast Cancer ◽

Computed Tomography ◽

Positron Emission Tomography ◽

Prospective Study ◽

Emission Tomography ◽

Positron Emission ◽

Pet Ct ◽

18F Fdg ◽

Early Primary ◽

A Prospective Study

Download Full-text

Interim 18F-FDG Positron Emission Tomography/Computed Tomography During Chemoradiotherapy in the Management of Cancer Patients

Clinical Oncology ◽

10.1016/j.clon.2019.01.008 ◽

2019 ◽

Vol 31 (4) ◽

pp. 267-268 ◽

Cited By ~ 1

Author(s):

C. Garibaldi ◽

M. Ferrari ◽

C.M. Grana ◽

B.A. Jereczek-Fossa ◽

M. Cremonesi

Keyword(s):

Computed Tomography ◽

Positron Emission Tomography ◽

Cancer Patients ◽

Emission Tomography ◽

Positron Emission ◽

18F Fdg

Download Full-text

Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma

Molecules ◽

10.3390/molecules25010134 ◽

2019 ◽

Vol 25 (1) ◽

pp. 134 ◽

Cited By ~ 1

Author(s):

Christos Sachpekidis ◽

Hartmut Goldschmidt ◽

Antonia Dimitrakopoulou-Strauss

Keyword(s):

Computed Tomography ◽

Positron Emission Tomography ◽

Multiple Myeloma ◽

Bone Marrow ◽

Bone Disease ◽

Emission Tomography ◽

Whole Body ◽

Positron Emission ◽

Pet Ct ◽

18F Fdg

Multiple myeloma (MM) is a plasma cell disorder, characterized by clonal proliferation of malignant plasma cells in the bone marrow. Bone disease is the most frequent feature and an end-organ defining indicator of MM. In this context, imaging plays a pivotal role in the management of the malignancy. For several decades whole-body X-ray survey (WBXR) has been applied for the diagnosis and staging of bone disease in MM. However, the serious drawbacks of WBXR have led to its gradual replacement from novel imaging modalities, such as computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT). PET/CT, with the tracer 18F-fluorodeoxyglucose (18F-FDG), is now considered a powerful diagnostic tool for the detection of medullary and extramedullary disease at the time of diagnosis, a reliable predictor of survival as well as the most robust modality for treatment response evaluation in MM. On the other hand, 18F-FDG carries its own limitations as a radiopharmaceutical, including a rather poor sensitivity for the detection of diffuse bone marrow infiltration, a relatively low specificity, and the lack of widely applied, established criteria for image interpretation. This has led to the development of several alternative PET tracers, some of which with promising results regarding MM detection. The aim of this review article is to outline the major applications of PET/CT with different radiopharmaceuticals in the clinical practice of MM.

Download Full-text